Laatste nieuws & blog
-
Roald Kruit shares his personal journey
In the latest Dutch Dragons episode, Roald Kruit shares his personal journey – from co-founding Mendix to founding Yamicc. It’s a story about entrepreneurship, technology, and above all, the conviction that we can (and should) do better when it comes to clinical research for rare cancers.Yamicc was born from the belief that research can be…
-
Kicking off 2026 – From vision to impact!
Last week marked our Yamicc Annual Kick-Off: a moment to reflect on what we have accomplished and align on where we’re going.This year, we are aiming for tangible impact: delivering operational excellence in practice through our Yamicc Platform. What we shared: • Strategic priorities from our 2026 plan• A live demo of the Yamicc Platform•…
-
You and Me in Action!
In 2026, we’re launching a movement. Literally.With Yamicc On the Move, we start the year with a motivated and growing community of people who choose to move! We take action for one shared goal: finding effective treatments for patients with rare cancer.On April 12, 2026, we’ll set the pace by running and cheering during the NN…
-
Welcoming Tom Peeters as Integration Architect!
We’re very excited to announce that Tom Peeters is joining Yamicc as our new Integration Architect, strengthening the technical foundation that underpins our mission to accelerate collaboration in rare cancer research.Tom brings years of experience in designing, building, and scaling integration architectures, with a deep understanding of how systems, data, and users interact in complex…
-
The Challenge in Clinical Trial Execution
Clinical trials are the engine of medical progress.But today, they still take a lot of time, are relatively expensive and aren’t built for flexibility.In rare cancer, where time is limited and patient populations are small, traditional trials often struggle to deliver meaningful results.Much of that comes down to infrastructure: Setting up studies takes months. Processes…
-
The Challenge of Facilitated Cooperation
In rare cancer research, collaboration is essential. And the willingness to work together is there. But supportive infrastructure is missing.Clinical studies take place within few hospitals, thereby not including all available patients. That limits scale, makes data hard to combine, and slows down progress.Differences in research design, legal frameworks, data storage and technology make it…
-
Josje van den Bos joins Yamicc as our new General Manager
Yamicc Team Update: We’re thrilled to announce that Josje van den Bos joins Yamicc as our new General Manager, leading the organization into its next phase of growth and impact.With a proven record of driving transformation at the intersection of data, technology, and human collaboration, Josje brings deep experience from her leadership roles at Dentsu and…
-
We’re proud and excited to join forces with SUPERP to accelerate our mission!
We’re proud and excited to join forces with SUPERP to accelerate our mission!Superp’s expertise helps strengthen the foundation we’re building for cheaper, faster, and smarter trials for patients with rare cancer. Enabling real impact takes more than science alone: it takes a shared ambition, strong infrastructures, and trusted partners.Thanks for standing with us! Read more…
-
On a mission: effective treatments for rare cancer patients
On a mission: effective treatments for rare cancer patients. One year of progress.On the 9th of October, Stichting Yamicc celebrated its first official anniversary! A milestone, and a great moment to reflect.We are laying the foundation to make clinical trials for rare cancers cheaper, faster, and more effective. Here’s a glimpse of what has happened…
-
Yamicc Explained: Why rare cancers need a different approach
Why rare cancers need a different approachOne in two people get cancer.One in five cancer patients is diagnosed with a rare form of the disease.But while oncology has advanced rapidly, traditional research models still fall short for rare cancer patients, because they weren’t built for this kind of complexity.Rare cancers are often biologically diverse and…